CORT
Corcept Therapeutics Incorporated81.12
-6.18-7.08%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Pricing stabilized, pharmacy fixed
Q&A offered granular color on Korlym pricing, with AG mix stabilizing near 78% after hitting 75% year-end, and guidance baking in discounts yet expecting demand surge post-pharmacy fix. Management confirmed all patients transitioned to scalable new vendor, tracking record February starts. ROSELLA safety mirrored topline, with fewer ALT rises in combo arm versus nab-paclitaxel alone; Keytruda faces biomarker hurdles allowing optionality. CRL daylight acknowledged via 'curious' elements, but merits defended. Pharmacy woes over. April FDA meeting and SGO data loom large for relacorilant paths.
Key Stats
Market Cap
8.55BP/E (TTM)
93.24Basic EPS (TTM)
0.87Dividend Yield
0%Recent Filings
8-K
Q4 2025 earnings released
Corcept Therapeutics reported 2025 revenue of $761.4 million, up from $675.0 million, driven by surging Cushing's syndrome demand and record new prescriptions despite pharmacy transition disruptions. Net income fell to $99.7 million from $141.2 million amid higher SG&A. Growth accelerates: 2026 revenue guided at $900–$1,000 million. Relacorilant NDAs advance toward approvals.
10-K
FY2025 results
Corcept Therapeutics' 10-K for FY2025 ended December 31, 2025 lacks financial statements, precluding quantitative analysis of annual or Q4 results. Key Q4 developments include transitioning specialty pharmacy services from Optime Care to Curant Health, with substantially all services transferred by year-end and full transition effective January 8, 2026; this supports Korlym and authorized generic distribution. Signed June 2025 master pharmacy agreement and SOWs, plus amendments through December 2025 adding relacorilant and full hub services starting January 2026. Expanded office sublease to 100% of building via December 2025 amendment, with phased delivery January-March 2026. No capex, debt, or guidance disclosed. Patent disputes could disrupt product sales.
8-K
Korlym patent appeal lost
Corcept Therapeutics lost a Federal Circuit appeal on February 19, 2026, affirming that Teva's generic Korlym doesn't infringe two patents on safely co-administering it with CYP3A4 inhibitors common in Cushing's syndrome treatment. The company expressed disappointment yet plans vigorous defense through potential judicial review. Patents matter daily for physicians.
8-K
ROSELLA OS endpoint met
Corcept's Phase 3 ROSELLA trial hit its overall survival endpoint, showing relacorilant plus nab-paclitaxel cut death risk 35% (HR 0.65, median OS 16.0 vs 11.9 months) in platinum-resistant ovarian cancer patients. Both primary endpoints met without added safety issues. ROSELLA succeeded. NDA PDUFA date is July 11, 2026; full results pending at medical conference.
8-K
FDA rejects relacorilant NDA
Corcept Therapeutics received an FDA Complete Response Letter on December 31, 2025, for relacorilant's NDA in hypertension secondary to hypercortisolism, despite GRACE trial meeting its primary endpoint and GRADIENT providing confirmatory data. The agency demands more effectiveness evidence for approval. Company plans FDA meeting soon. Relacorilant awaits PDUFA July 11, 2026, for ovarian cancer.
ALT
Altimmune, Inc.
5.03-0.25
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
CRMD
CorMedix Inc.
11.44+0.11
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
KRRO
Korro Bio, Inc.
8.22+0.26
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
RLMD
Relmada Therapeutics, Inc.
4.50+0.14
RZLT
Rezolute, Inc.
2.02+0.39
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05